Press Releases

Annie Murphy shares her birth control journey and why she selected Phexxi® (lactic acid, citric acid and potassium bitartrate) as her hormone-free, on-demand prescription birth control

-- 68% increase in net product sales Q1 to Q2 --

-- Conference Call Scheduled for 4:30 p.m. ET -

- High Percentage of Women Converting to Phexxi from Hormonal Birth Control -

-- Company Would Receive up to an Additional $50 Million Upon Exercise of Accompanying Short-Term Warrants --

-- Qualitative Research found Product Satisfaction and the Impact of EVO100 on Sexual Satisfaction were Important and Meaningful to Assess and would be Tied to Product Use --

- Potential for Expedited NDA Review of EVO100 by FDA -

-- Net Revenues Increased 550% Compared to 2020 Fourth Quarter --

-- Conference Call Scheduled for 4:30 p.m. ET --

Posters Focus on Perfect-Use Efficacy Data and Sexual Satisfaction and Function Among Women in the Phase 3 AMPOWER Trial

- Over 2,400 Phexxi units dispensed in February 2021, up 30% from prior month -

-- Phexxi® (lactic acid, citric acid and potassium bitartrate) vaginal gel prescriptions growing month over month, catalyzed by "Get Phexxi" Direct-to-Consumer (DTC) Campaign launched February 14th --

-- Conference Call Scheduled for 4:30 p.m. ET --